Rafael Panc003- A Phase III Multicenter Open-Label Randomized Trial To Evaluate Efficacy And Safety Of Folfirinox (Ffx) Versus Combination Of Cpi-613 With Modified Folfirinox (Mffx) In Patients With Metastatic Adenocarcinoma Of The Pancreas
Posted Date: Sep 4, 2020
- Investigator: Davendra Sohal
- Specialties: Cancer, Oncology, Pancreatic Cancer
- Type of Study: Drug
This is a prospective, multicenter, open label, randomized phase III study to evaluate efficacy and safety of FFX versus CPI-613 + mFFX in patients with metastatic adenocarcinoma of the pancreas with age range of 18 to 75 years. The primary outcome of this study is to determine Objective Response Rate.
Criteria:
To Be Eligible: Must Have Diagnosis Of Stage Iv Adenocarcinoma Of The Pancreas, Ecog 0-1, Age 18-75, Expected Survival >3 Months, No Prior Treatment For Study Cancer, No Hypersensitivity To Devimistat, Ffx Treatment Or Any Of Their Excipients, No Serious Medical Illness That Would Potentially Increase Patients' Risk For Toxicity
Keywords:
Pancreatic Cancer, Adenocarcinoma
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com